[Interleukin-2 immunotherapy and cutaneous manifestations].
The cutaneous manifestations which follow the administration of recombinant interleukin-2 (rIL-2) are well known, but their nature and severity have not yet been fully studied. The authors report the dermatological changes observed in 12 patients treated with rIL-2 for renal cancer. The predominant lesion was generalized erythema followed by desquamation.
Larbre
B
B
Clinique Dermatologique, Hôpital Edouard Herriot, Lyon.
Nicolas
J F
JF
Sarret
Y
Y
Tognet
E
E
Mercatello
A
A
Thivolet
J
J
D000328:Adult; D000368:Aged; D002985:Clinical Protocols; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D004890:Erythema / Q000139:chemically induced / Q000473:pathology; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods*; D007376:Interleukin-2 / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000556:secondary*; D015979:Killer Cells, Lymphokine-Activated; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D007376:Interleukin-2
Immunothérapie par interleukine 2 et manifestations cutanées.